

●▶ **Jazz Pharmaceuticals**

(FDA, Approval)

FDA approved Jazz Pharmaceuticals' MODEYSO (dordaviprone) for the treatment of recurrent H3 K27M-mutant diffuse midline glioma

●▶ **Celltrion**

(FDA, Approval)

FDA approved Celltrion's expanded indication for AVTOZMA (biosimilar version of ACTEMRA) intravenous (IV) for the treatment of cytokine release syndrome (CRS)

●▶ **Boehringer Ingelheim**

(FDA, Approval)

FDA granted accelerated approval to Boehringer's HERNEXEOS® for patients with HER2-mutant advanced NSCLC who have undergone treatment

●▶ **Teva Pharmaceuticals**

(FDA, Approval)

FDA approved an expanded indication for Teva's AJOVY (fremanezumab-vfrm) for pediatric patients suffering from episodic migraine



●▶ **Nyxoah**

(FDA, Medical Device)

FDA approved Nyxoah's GENIO System for the treatment of obstructive sleep apnea

●▶ **Kedrion Biopharma**

(FDA, Orphan Drug Designation)

Kedrion received orphan drug designation from the FDA for ceruloplasmin for the treatment of Congenital Aceruloplasminemia

●▶ **Ouro Medicines**

(FDA, Orphan Drug Designation)

Ouro Medicines initiated a Ph1b basket study of OM336 focused on autoimmune cytopenias and received orphan drug designation from the FDA in autoimmune hemolytic anemia (AIHA)

●▶ **Arvinas**

(FDA, NDA)

FDA accepted the NDA for Arvinas' vepdegestrant for the treatment of advanced breast cancer that is ESR1-mutant, ER-positive and HER2-negative



●► **Sanofi**

(Acquisition)

Sanofi completed the acquisition of Vigil Neuroscience for the development of its TREM2 agonist VG-3927 for AD

●► **Melinta Therapeutics**

(Acquisition)

CorMedix acquired Melinta Therapeutics in a strategic deal for developing and commercializing therapeutic products for life-threatening diseases

●► **GSK**

(FDA, Priority Review)

FDA accepted GSK's gepotidacin for priority review as an oral treatment for uncomplicated urogenital gonorrhoea



●▶ **Click Therapeutics**

(Clinical Trial Result)

Boehringer Ingelheim and Click Therapeutics' CT-155 met the primary endpoint in the CONVOKE study as reduction in experiential negative symptoms as an adjunct to standard of care antipsychotic therapy

●▶ **Novartis**

(Clinical Trial Result)

Novartis' ionalumab met the primary endpoints in the two Phase 3 trials in Sjögren's disease; demonstrating statistically significant improvements in disease activity

